

**VCUHS ANTIFUNGAL SUSCEPTIBILITY TABLES  
JANUARY – DECEMBER 2023  
Department of Pathology - Microbiology/Immunology**

**Table 1. Activity of selected antifungals against yeast**

Percentage (%) of Organisms Susceptible				
Organism	Number Tested	Micafungin	Fluconazole <sup>b</sup>	Voriconazole
<i>Candida albicans</i>	65	100	92	92
<i>Candida glabrata</i>	48	95	81	- <sup>a</sup>
<i>Candida parapsilosis</i>	56 <sup>c</sup>	100	98	98
<i>Candida auris</i> <sup>d</sup>	30 <sup>c</sup>	76	0	

<sup>a</sup> Current data are insufficient to demonstrate a correlation between *in vitro* susceptibility testing and clinical outcomes per CLSI M100 guidelines.

<sup>b</sup> Fluconazole results include Susceptible Dose Dependent (SDD) isolates.

<sup>c</sup> Data included from January 2022 until December 2023 due to data with fewer than 30 isolates being considered statistically unreliable.

<sup>d</sup> There are currently no established *C. auris*-specific susceptibility breakpoints. The interpretations given should be considered as a general guide and not as definitive breakpoints for resistance. These CDC tentative breakpoints are defined based on those established for closely related *Candida* species and on expert opinion.

**Data collected by the Clinical Microbiology Laboratory, Department of Pathology  
CLSI M100-ed33 and M27M44-ed3 Interpretation breakpoints were applied unless otherwise stated.**